Literature DB >> 217828

Host defenses in herpes simplex infections of the nervous system: effect of antibody on disease and viral spread.

R R McKendall, T Klassen, J R Baringer.   

Abstract

BALB/c mice passively immunized with antibody to herpes simplex virus type 1 and challenged in the footpad with 10(5.7) plaque-forming units of herpes simplex virus type 1 were shown to be protected from neurological disease and death compared with control mice treated with normal serum or antibody to Sindbis virus. One hundred percent of untreated mice had virus recoverable from dorsal root ganglia by 48 h after infection. Whereas amputation of the infected limb at 48 h had no effect, antibody administration (resulting in titers of 1:8 and 1:16) was found to prevent acute neurological disease if administered no later than 48 h after infection. Antibody also restricted the extent of latent infection in the lumbosacral ganglia. The data provide strong evidence that antibody is effective in preventing spread of virus both in the peripheral nervous system and in central nervous system (spinal cord) tissue.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 217828      PMCID: PMC414165          DOI: 10.1128/iai.23.2.305-311.1979

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Viral spread in the presence of neutralizing antibody: mechanisms of persistence in foamy virus infection.

Authors:  J J Hooks; W Burns; K Hayashi; S Geis; A L Notkins
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

2.  Pathogenesis of herpes simplex virus types 1 and 2 in mice after various routes of inoculation.

Authors:  H E Renis; E E Eidson; J Mathews; J E Gray
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

3.  Pathogenesis of herpetic neuritis and ganglionitis in mice: evidence for intra-axonal transport of infection.

Authors:  M L Cook; J G Stevens
Journal:  Infect Immun       Date:  1973-02       Impact factor: 3.441

4.  Herpes virus latency in spinal ganglia of mice without illness.

Authors:  R R McKendall; N Vogelzang; G G Jackson
Journal:  Proc Soc Exp Biol Med       Date:  1974-09

5.  A prospective study of chronic herpes simplex virus infection and recurrent herpes labialis in humans.

Authors:  R G Douglas; R B Couch
Journal:  J Immunol       Date:  1970-02       Impact factor: 5.422

6.  Spread of herpes simplex virus in peripheral nerves.

Authors:  K Kristensson; E Lycke; J Sjöstrand
Journal:  Acta Neuropathol       Date:  1971       Impact factor: 17.088

7.  Minicultures of mammalian cells in a new plastic plate.

Authors:  D A Fuccillo; L W Catalano; F L Moder; D A Debus; J L Sever
Journal:  Appl Microbiol       Date:  1969-04

8.  Morphological studies of the neural spread of herpes simplex virus to the central nervous system.

Authors:  K Kristensson
Journal:  Acta Neuropathol       Date:  1970       Impact factor: 17.088

9.  The natural history of recurrent herpes simplex labialis: implications for antiviral therapy.

Authors:  S L Spruance; J C Overall; E R Kern; G G Krueger; V Pliam; W Miller
Journal:  N Engl J Med       Date:  1977-07-14       Impact factor: 91.245

10.  THE PATHOGENESIS OF HERPES VIRUS ENCEPHALITIS. I. VIRUS PATHWAYS TO THE NERVOUS SYSTEM OF SUCKLING MICE DEMONSTRATED BY FLUORESCENT ANTIBODY STAINING.

Authors:  R T JOHNSON
Journal:  J Exp Med       Date:  1964-02-01       Impact factor: 14.307

View more
  33 in total

1.  Pathogenesis of herpes simplex virus-induced ocular immunoinflammatory lesions in B-cell-deficient mice.

Authors:  S P Deshpande; M Zheng; M Daheshia; B T Rouse
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

Review 2.  Role of antibodies in controlling viral disease: lessons from experiments of nature and gene knockouts.

Authors:  P P Sanna; D R Burton
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.

Authors:  Sarat K Dalai; Lesley Pesnicak; Georgina F Miller; Stephen E Straus
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

4.  Prevention and treatment of experimental herpes simplex virus encephalitis with human immune serum globulin.

Authors:  K S Erlich; R D Dix; J Mills
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

5.  Herpes simplex virus, type 1 invasion of the rabbit and mouse nervous systems revealed by in situ hybridization.

Authors:  W G Stroop; D C Schaefer
Journal:  Acta Neuropathol       Date:  1987       Impact factor: 17.088

6.  Vaccine-induced serum immunoglobin contributes to protection from herpes simplex virus type 2 genital infection in the presence of immune T cells.

Authors:  L A Morrison; L Zhu; L G Thebeau
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

7.  Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing).

Authors:  H W Virgin; R Bassel-Duby; B N Fields; K L Tyler
Journal:  J Virol       Date:  1988-12       Impact factor: 5.103

8.  Monoclonal antibodies suppress replication of herpes simplex virus type 1 in trigeminal ganglia.

Authors:  J E Oakes; R N Lausch
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

9.  Impact of valency of a glycoprotein B-specific monoclonal antibody on neutralization of herpes simplex virus.

Authors:  Adalbert Krawczyk; Jürgen Krauss; Anna M Eis-Hübinger; Martin P Däumer; Robert Schwarzenbacher; Ulf Dittmer; Karl E Schneweis; Dirk Jäger; Michael Roggendorf; Michaela A E Arndt
Journal:  J Virol       Date:  2010-12-01       Impact factor: 5.103

10.  Experimental skin infection with an acyclovir resistant herpes simplex virus mutant: response to antiviral treatment and protection against reinfection.

Authors:  R J Klein; E DeStefano; E Brady; A E Friedman-Kien
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.